[go: up one dir, main page]

BRPI1008044A2 - suporte de afinidade para a fixacao seletiva de uma proteina do plasma sanguineo, processos para imobilizar uma proteina plasmatica sobre um suporte, e para purificar uma proteina plasmatica, composicao purificada de uma proteina plasmatica humana recombinante e composicao farmaceutica - Google Patents

suporte de afinidade para a fixacao seletiva de uma proteina do plasma sanguineo, processos para imobilizar uma proteina plasmatica sobre um suporte, e para purificar uma proteina plasmatica, composicao purificada de uma proteina plasmatica humana recombinante e composicao farmaceutica

Info

Publication number
BRPI1008044A2
BRPI1008044A2 BRPI1008044A BRPI1008044A BRPI1008044A2 BR PI1008044 A2 BRPI1008044 A2 BR PI1008044A2 BR PI1008044 A BRPI1008044 A BR PI1008044A BR PI1008044 A BRPI1008044 A BR PI1008044A BR PI1008044 A2 BRPI1008044 A2 BR PI1008044A2
Authority
BR
Brazil
Prior art keywords
plasma protein
support
immobilizing
purifying
processes
Prior art date
Application number
BRPI1008044A
Other languages
English (en)
Inventor
Gerald Perret
Michael Nogre
Original Assignee
Lfb Biotechnologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies filed Critical Lfb Biotechnologies
Publication of BRPI1008044A2 publication Critical patent/BRPI1008044A2/pt
Publication of BRPI1008044A8 publication Critical patent/BRPI1008044A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
BRPI1008044A 2009-02-19 2010-02-19 suporte de afinidade para a fixação seletiva de uma proteína do plasma sanguíneo, processos para imobilizar uma proteína plasmática sobre um suporte, e para purificar uma proteína plasmática, composição purificada de uma proteína plasmática humana recombinante e composicao farmacêutica BRPI1008044A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0951083A FR2942233B1 (fr) 2009-02-19 2009-02-19 Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
PCT/FR2010/050294 WO2010094901A1 (fr) 2009-02-19 2010-02-19 Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en œuvre

Publications (2)

Publication Number Publication Date
BRPI1008044A2 true BRPI1008044A2 (pt) 2016-05-03
BRPI1008044A8 BRPI1008044A8 (pt) 2018-04-03

Family

ID=41319742

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008044A BRPI1008044A8 (pt) 2009-02-19 2010-02-19 suporte de afinidade para a fixação seletiva de uma proteína do plasma sanguíneo, processos para imobilizar uma proteína plasmática sobre um suporte, e para purificar uma proteína plasmática, composição purificada de uma proteína plasmática humana recombinante e composicao farmacêutica

Country Status (14)

Country Link
US (1) US9534012B2 (pt)
EP (1) EP2398818B1 (pt)
JP (2) JP6129473B2 (pt)
KR (1) KR101713761B1 (pt)
CN (1) CN102405228B (pt)
AU (1) AU2010215304B2 (pt)
BR (1) BRPI1008044A8 (pt)
CA (1) CA2753172A1 (pt)
DK (1) DK2398818T3 (pt)
ES (1) ES2700225T3 (pt)
FR (1) FR2942233B1 (pt)
IL (1) IL214567A (pt)
PL (1) PL2398818T3 (pt)
WO (1) WO2010094901A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948665B1 (fr) * 2009-07-31 2011-09-23 Lfb Biotechnologies Procede pour la purification de proteines de la coagulation a domaine gla actives
FR2948664B1 (fr) * 2009-07-31 2013-11-01 Lfb Biotechnologies Procede pour la purification de proteines de la coagulation a domaine gla
FR2983212A1 (fr) * 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
EP2687595B1 (en) * 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
CA3129057C (en) * 2012-10-03 2023-03-07 Csl Behring Ag A method of purifying proteins
ES2692408T3 (es) 2013-01-20 2018-12-03 Dyax Corp. Evaluación y tratamiento de trastornos mediados por bradiquinina
CA2909139C (en) 2013-04-18 2021-07-06 Institut National De La Sante Et De La Recherche Medicale Composition with reduced immunogenicity
EP2821076A1 (en) 2013-07-02 2015-01-07 Stallergenes Sa C1q as a therapeutic agent of allergy and/or asthma
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
WO2015066080A2 (en) * 2013-10-28 2015-05-07 The Regents Of The University Of California Lipid co-factor essential for cell density signaling
FR3018450B1 (fr) * 2014-03-11 2016-04-15 Lab Francais Du Fractionnement Procede de preparation de proteines plasmatiques humaines
EP2974741A1 (en) 2014-07-16 2016-01-20 Stallergenes Composition of allergen extracts having reduced toxicity and method of production thereof
US11725044B2 (en) 2014-10-15 2023-08-15 Xenothera Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
JP6903648B2 (ja) * 2015-10-19 2021-07-14 ダイアックス コーポレーション 切断高分子量キニノーゲンを検出するイムノアッセイ
WO2018007530A1 (en) 2016-07-06 2018-01-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anti-fibrinogen aptamers and uses thereof
WO2018019538A1 (en) * 2016-07-28 2018-02-01 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anti- immunoglobulin g aptamers and uses thereof
CN106148465B (zh) * 2016-08-09 2020-02-14 广东海洋大学 一种具有抗氧化活性的鲎血浆蛋白水解肽及其制备方法和应用
CA3035650A1 (en) 2016-09-01 2018-03-08 Plas-Free Ltd Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
WO2020079108A1 (en) * 2018-10-17 2020-04-23 Csl Behring Gmbh Process for purifying c1-inh
AU2020266993A1 (en) 2019-04-30 2022-01-06 Xenothera Association of polyclonal antibodies and anti-PD1 or anti-PDL1 antibodies for the treatment of cancer
GB201906595D0 (en) * 2019-05-10 2019-06-26 Ge Healthcare Bioprocess R&D Ab Method for purification of plasma proteins
CN111000974B (zh) * 2020-02-24 2021-07-27 重庆大学 一种兔奶活性小肽溶液及其提取方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440018A (en) 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JP2869417B2 (ja) 1992-09-22 1999-03-10 吉富製薬株式会社 遺伝子操作により得られるヒト血清アルブミン
US5521287A (en) * 1992-05-20 1996-05-28 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JP3508149B2 (ja) 1993-02-25 2004-03-22 三菱ウェルファーマ株式会社 ヒト血清アルブミンおよびその製造方法
CA2116385A1 (en) 1993-02-25 1994-08-26 Akinori Sumi Human serum albumin and process for producing the same
US6117996A (en) * 1995-09-20 2000-09-12 Novo Nordisk A/S Triazine based ligands and use thereof
US7312325B2 (en) * 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
JP4970260B2 (ja) * 2004-08-20 2012-07-04 プロメティック バイオサイエンシズ，リミテッド 親和性クロマトグラフィーによるタンパク質の逐次的単離および精製スキーム
CA2622765A1 (en) * 2005-09-15 2007-03-29 Duke University Focused libraries, functional profiling, laser selex and deselex
EP1951394A4 (en) * 2005-11-21 2011-01-19 Ge Healthcare Bio Sciences Ab CHROMATOGRAPHY PROCEDURES USING HALF-SYNTHETIC HEPARIN LIGANDS
FR2910786B1 (fr) * 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"

Also Published As

Publication number Publication date
WO2010094901A1 (fr) 2010-08-26
ES2700225T3 (es) 2019-02-14
CN102405228B (zh) 2016-08-24
AU2010215304A1 (en) 2011-09-08
FR2942233B1 (fr) 2015-03-13
PL2398818T3 (pl) 2019-02-28
EP2398818A1 (fr) 2011-12-28
IL214567A0 (en) 2011-09-27
FR2942233A1 (fr) 2010-08-20
DK2398818T3 (da) 2019-01-02
BRPI1008044A8 (pt) 2018-04-03
KR20110139199A (ko) 2011-12-28
US9534012B2 (en) 2017-01-03
JP6129473B2 (ja) 2017-05-17
EP2398818B1 (fr) 2018-08-29
JP2012518033A (ja) 2012-08-09
KR101713761B1 (ko) 2017-03-08
CA2753172A1 (fr) 2010-08-26
IL214567A (en) 2016-12-29
AU2010215304B2 (en) 2015-08-13
JP2016028027A (ja) 2016-02-25
CN102405228A (zh) 2012-04-04
US20120122179A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
BRPI1008044A2 (pt) suporte de afinidade para a fixacao seletiva de uma proteina do plasma sanguineo, processos para imobilizar uma proteina plasmatica sobre um suporte, e para purificar uma proteina plasmatica, composicao purificada de uma proteina plasmatica humana recombinante e composicao farmaceutica
BRPI1008043A2 (pt) suporte de afinidade para fixação seletiva de uma proteína da coagulação, processos para imobilizar uma proteína da coagulação sobre um suporte e para purificar uma proteína da coagulação humana recombinante, e composição farmacêutica
BRPI1014508A2 (pt) análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso"
DE502007004174D1 (de) Markerkomposit für medizinische Implantate
EP2226331A4 (en) PROCESS FOR CLEANING PROTEINS
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
EP2132133A4 (en) RELEASE OF PARTICULATE ACTIVE SUBSTANCES
BRPI1016147A2 (pt) sistema intrauterino para uso no tratamento de uma condição médica, e, método para a fabricação de um sistema intrauterino
BR112013011968A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
NO20091545L (no) Fremgangsmåte for levering av medikament for ben-anabolt protein
PL2285408T3 (pl) Sekwencje aminokwasowe skierowane przeciwko białkom otoczki wirusa i polipeptydy je zawierające do leczenia chorób wirusowych
EP2116269A4 (en) Blood purification system
IL200330A0 (en) Recombinant antibodies for treatment of respiratory syncytial virus infections
EP2353532A4 (en) SYSTEM AND METHOD FOR SURGICAL CONTROL
BRPI0812134A2 (pt) Anatagonistas de cxcr4 de peptídio cíclico
CU23828B1 (es) Derivados de dihidropiridina de utilidad como inhibodires de la proteína quinasa
BRPI0812738A2 (pt) Composto, sal farmceuticamente aceitável, composição farmacêutica, uso de um composto, e, método par ao tratamento de uma infecção viral em um humano
DK2109432T3 (da) Behandlingssystem til repositionering af patient og legemsdel
BRPI0911259A2 (pt) composto, composição farmacêutica, método de inibição da atividade da polimerase de ns5b in vitro e usos de compostos
BRPI0715715A2 (pt) Atuador para um inalador para distribuir medicamento por inalação, inalador, e, kit de partes
PT2236149E (pt) Composição medicinal para o tratamento de doenças infeciosas respiratórias
BR112013009294A2 (pt) componente dental, fixação dental, conjunto de implante dental e sistema de implante dental
BRPI0807597A2 (pt) Composição farmacêutica, e, método para tratar infecção por vírus da influenza
IL202450A (en) Pharmaceutical composition to treat influenza virus infection
DK3479863T3 (da) Sammensætninger, fremgangsmåder og artikler indeholdende farmaceutisk nitrogenoxid og regulerede leveringssystemer deraf til patienter

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOT

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2619 DE 16-03-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.